$MDGL
Madrigal Pharmaceuticals Inc Stock $mdgl

$mdgl Overview Financials Valuation SEC Filings Company Website

2024 Q2 Form 10-Q Financial Statement

#000162828024020865 Filed on May 07, 2024

Income Statement

Concept	2024 Q2	2024 Q1	2023 Q4
Revenue	$14.64M	$0.00	$0.00
YoY Change
Cost Of Revenue	$636.0K
YoY Change
Gross Profit	$14.00M
YoY Change
Gross Profit Margin	95.66%
Selling, General & Admin	$105.4M	$80.80M	$46.54M
YoY Change	490.91%	399.32%	219.68%
% of Gross Profit	753.09%
Research & Development	$71.09M	$71.24M	$70.64M
YoY Change	3.62%	14.61%	-0.14%
% of Gross Profit	507.72%
Depreciation & Amortization	$267.0K	$168.0K	$142.0K
YoY Change	111.9%	35.48%	10.08%
% of Gross Profit	1.91%
Operating Expenses	$177.2M	$152.0M	$117.2M
YoY Change	104.95%	94.08%	37.37%
Operating Profit	-$162.5M	-$152.0M	-$117.2M
YoY Change	88.01%	94.08%	37.37%
Interest Expense	$3.656M	$3.838M	$3.971M
YoY Change	26.03%	64.3%	136.09%
% of Operating Profit
Other Income/Expense, Net			$0.00
YoY Change
Pretax Income	-$152.0M	-$147.5M	-$112.2M
YoY Change	77.12%	91.87%	30.6%
Income Tax
% Of Pretax Income
Net Earnings	-$152.0M	-$147.5M	-$112.2M
YoY Change	77.12%	91.81%	30.6%
Net Earnings / Revenue	-1038.2%
Basic Earnings Per Share	-$7.10	-$7.38	-$5.68
Diluted Earnings Per Share	-$7.10	-$7.38	-$5.68
COMMON SHARES
Basic Shares Outstanding	21.31M shares	19.90M shares	19.74M
Diluted Shares Outstanding	21.40M shares	20.00M shares	19.76M shares

Balance Sheet

Concept	2024 Q2	2024 Q1	2023 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments	$1.058B	$1.059B	$634.1M
YoY Change	254.47%	221.44%	76.75%
Cash & Equivalents	$494.6M	$622.5M	$99.92M
Short-Term Investments	$563.2M	$436.5M	$534.2M
Other Short-Term Assets		$14.04M	$3.150M
YoY Change		676.7%	21.39%
Inventory	$7.072M	$854.0K	$0.00
Prepaid Expenses
Receivables	$6.899M		$0.00
Other Receivables
Total Short-Term Assets	$1.092B	$1.074B	$637.3M
YoY Change	261.98%	224.18%	76.35%
LONG-TERM ASSETS
Property, Plant & Equipment	$1.695M	$1.742M	$1.553M
YoY Change	272.53%	240.23%	158.4%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets	$8.061M	$8.328M	$3.266M
YoY Change	830.83%	614.85%	171.49%
TOTAL ASSETS
Total Short-Term Assets	$1.092B	$1.074B	$637.3M
Total Long-Term Assets	$8.061M	$8.328M	$3.266M
Total Assets	$1.100B	$1.082B	$640.5M
YoY Change	263.61%	225.55%	76.67%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$8.994M	$21.53M	$28.04M
YoY Change	-48.71%	77.51%	17.67%
Accrued Expenses	$115.6M	$92.27M	$89.98M
YoY Change	41.4%	7.83%	-1.62%
Deferred Revenue
YoY Change
Short-Term Debt		$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$125.2M	$114.3M	$118.5M
YoY Change	25.53%	16.26%	2.29%
LONG-TERM LIABILITIES
Long-Term Debt	$116.6M	$116.1M	$115.5M
YoY Change	17.49%	38.31%	134.29%
Other Long-Term Liabilities		$1.045M	$1.186M
YoY Change
Total Long-Term Liabilities	$117.5M	$117.2M	$116.7M
YoY Change	18.4%	39.56%	136.7%
TOTAL LIABILITIES
Total Short-Term Liabilities	$125.2M	$114.3M	$118.5M
Total Long-Term Liabilities	$117.5M	$117.2M	$116.7M
Total Liabilities	$242.7M	$231.5M	$235.2M
YoY Change	21.97%	26.99%	42.4%
SHAREHOLDERS EQUITY
Retained Earnings	-$1.636B	-$1.484B	-$1.336B
YoY Change	45.4%	42.67%	38.81%
Common Stock	$2.493B	$2.335B	$1.741B
YoY Change	102.88%	96.24%	50.09%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$857.1M	$850.8M	$405.3M
YoY Change
Total Liabilities & Shareholders Equity	$1.100B	$1.082B	$640.5M
YoY Change	263.61%	225.55%	76.67%

Cashflow Statement

Concept	2024 Q2	2024 Q1	2023 Q4
OPERATING ACTIVITIES
Net Income	-$152.0M	-$147.5M	-$112.2M
YoY Change	77.12%	91.81%	30.6%
Depreciation, Depletion And Amortization	$267.0K	$168.0K	$142.0K
YoY Change	111.9%	35.48%	10.08%
Cash From Operating Activities	-$134.9M	-$149.2M	-$79.93M
YoY Change	79.19%	77.43%	36.6%
INVESTING ACTIVITIES
Capital Expenditures	$5.131M	$357.0K	$1.036M
YoY Change	7336.23%	920.0%	3472.41%
Acquisitions
YoY Change
Other Investing Activities	-$117.0M	$98.41M	-$361.1M
YoY Change	3093.2%	-152.67%	-643.67%
Cash From Investing Activities	-$122.1M	$98.05M	-$362.1M
YoY Change	3171.65%	-152.47%	-645.47%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	134.1M	$573.7M	479.9M
YoY Change	212.42%	988.83%	81.55%
NET CHANGE
Cash From Operating Activities	-134.9M	-$149.2M	-79.93M
Cash From Investing Activities	-122.1M	$98.05M	-362.1M
Cash From Financing Activities	134.1M	$573.7M	479.9M
Net Change In Cash	-122.9M	$522.6M	37.86M
YoY Change	240.39%	-339.46%	-86.09%
FREE CASH FLOW
Cash From Operating Activities	-$134.9M	-$149.2M	-$79.93M
Capital Expenditures	$5.131M	$357.0K	$1.036M
Free Cash Flow	-$140.1M	-$149.5M	-$80.97M
YoY Change	85.83%	77.78%	38.3%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2024Q1	us-gaap	Available For Sale Securities Debt Securities Current AvailableForSaleSecuritiesDebtSecuritiesCurrent	436546000	usd
CY2023Q4	us-gaap	Available For Sale Securities Debt Securities Current AvailableForSaleSecuritiesDebtSecuritiesCurrent	534216000	usd
CY2024Q1	us-gaap	Inventory Net InventoryNet	854000	usd
CY2023Q4	us-gaap	Inventory Net InventoryNet	0	usd
CY2024Q1	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	14035000	usd
CY2023Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	3150000	usd
CY2024Q1	us-gaap	Assets Current AssetsCurrent	1073952000	usd
CY2023Q4	us-gaap	Assets Current AssetsCurrent	637281000	usd
CY2024Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1742000	usd
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1553000	usd
CY2024Q1	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	5000000	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	0	usd
CY2024Q1	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	1586000	usd
CY2023Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	1713000	usd
CY2024Q1	us-gaap	Assets Assets	1082280000	usd
CY2023Q4	us-gaap	Assets Assets	640547000	usd
CY2024Q1	us-gaap	Accounts Payable Current AccountsPayableCurrent	21528000	usd
CY2023Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	28041000	usd
CY2024Q1	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	92271000	usd
CY2023Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	89980000	usd
CY2024Q1	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	542000	usd
CY2023Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	527000	usd
CY2024Q1	us-gaap	Liabilities Current LiabilitiesCurrent	114341000	usd
CY2023Q4	us-gaap	Liabilities Current LiabilitiesCurrent	118548000	usd
CY2024Q1	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	116135000	usd
CY2023Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	115480000	usd
CY2024Q1	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	1045000	usd
CY2023Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	1186000	usd
CY2024Q1	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	117180000	usd
CY2023Q4	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	116666000	usd
CY2024Q1	us-gaap	Liabilities Liabilities	231521000	usd
CY2023Q4	us-gaap	Liabilities Liabilities	235214000	usd
CY2024Q1	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2023Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2023Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2024Q1	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2024Q1	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	2369797	shares
CY2024Q1	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	2369797	shares
CY2023Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	2369797	shares
CY2023Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	2369797	shares
CY2024Q1	us-gaap	Preferred Stock Value PreferredStockValue	0	usd
CY2023Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	usd
CY2023Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2024Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2023Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	200000000	shares
CY2024Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	200000000	shares
CY2023Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	20684663	shares
CY2023Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	20684663	shares
CY2024Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	19875427	shares
CY2024Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	19875427	shares
CY2024Q1	us-gaap	Common Stock Value CommonStockValue	2000	usd
CY2023Q4	us-gaap	Common Stock Value CommonStockValue	2000	usd
CY2024Q1	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	2334760000	usd
CY2023Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	1741153000	usd
CY2024Q1	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-172000	usd
CY2023Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	468000	usd
CY2024Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-1483831000	usd
CY2023Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-1336290000	usd
CY2024Q1	us-gaap	Stockholders Equity StockholdersEquity	850759000	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	405333000	usd
CY2024Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	1082280000	usd
CY2023Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	640547000	usd
CY2024Q1	us-gaap	Revenues Revenues	0	usd
CY2023Q1	us-gaap	Revenues Revenues	0	usd
CY2024Q1	us-gaap	Research And Development Expense Excluding Acquired In Process Cost ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost	71237000	usd
CY2023Q1	us-gaap	Research And Development Expense Excluding Acquired In Process Cost ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost	62154000	usd
CY2024Q1	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	80800000	usd
CY2023Q1	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	16182000	usd
CY2024Q1	us-gaap	Operating Expenses OperatingExpenses	152037000	usd
CY2023Q1	us-gaap	Operating Expenses OperatingExpenses	78336000	usd
CY2024Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-152037000	usd
CY2023Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-78336000	usd
CY2024Q1	us-gaap	Investment Income Interest InvestmentIncomeInterest	8334000	usd
CY2023Q1	us-gaap	Investment Income Interest InvestmentIncomeInterest	3776000	usd
CY2024Q1	us-gaap	Interest Expense InterestExpense	3838000	usd
CY2023Q1	us-gaap	Interest Expense InterestExpense	2336000	usd
CY2024Q1	us-gaap	Net Income Loss NetIncomeLoss	-147541000	usd
CY2024Q1	us-gaap	Net Income Loss NetIncomeLoss	-147541000	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-76896000	usd
CY2024Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-7.38
CY2024Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-7.38
CY2023Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-4.23
CY2023Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-4.23
CY2024Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	20001569	shares
CY2024Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	20001569	shares
CY2023Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	18187924	shares
CY2023Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	18187924	shares
CY2024Q1	us-gaap	Net Income Loss NetIncomeLoss	-147541000	usd
CY2024Q1	us-gaap	Net Income Loss NetIncomeLoss	-147541000	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-76896000	usd
CY2024Q1	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	-640000	usd
CY2023Q1	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	-54000	usd
CY2024Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-148181000	usd
CY2023Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-76950000	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	405333000	usd
CY2024Q1	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	311560000	usd
CY2024Q1	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	19902000	usd
CY2024Q1	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	-640000	usd
CY2024Q1	us-gaap	Net Income Loss NetIncomeLoss	-147541000	usd
CY2024Q1	us-gaap	Stockholders Equity StockholdersEquity	850759000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	197389000	usd
CY2023Q1	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	11250000	usd
CY2023Q1	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	-54000	usd
CY2023Q1	us-gaap	Adjustments To Additional Paid In Capital Warrant Issued AdjustmentsToAdditionalPaidInCapitalWarrantIssued	544000	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-76896000	usd
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	150136000	usd
CY2024Q1	us-gaap	Profit Loss ProfitLoss	-147541000	usd
CY2023Q1	us-gaap	Profit Loss ProfitLoss	-76896000	usd
CY2024Q1	us-gaap	Share Based Compensation ShareBasedCompensation	19902000	usd
CY2023Q1	us-gaap	Share Based Compensation ShareBasedCompensation	11250000	usd
CY2024Q1	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	168000	usd
CY2023Q1	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	124000	usd
CY2024Q1	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	655000	usd
CY2023Q1	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	433000	usd
CY2024Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	10885000	usd
CY2023Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-788000	usd
CY2024Q1	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	854000	usd
CY2023Q1	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	0	usd
CY2024Q1	us-gaap	Increase Decrease In Accounts Payable Trade IncreaseDecreaseInAccountsPayableTrade	-11513000	usd
CY2023Q1	us-gaap	Increase Decrease In Accounts Payable Trade IncreaseDecreaseInAccountsPayableTrade	-11703000	usd
CY2024Q1	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	2291000	usd
CY2023Q1	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-5894000	usd
CY2024Q1	mdgl	Increase Decrease In Accrued Interest Net Of Interest Received IncreaseDecreaseInAccruedInterestNetOfInterestReceived	-1380000	usd
CY2023Q1	mdgl	Increase Decrease In Accrued Interest Net Of Interest Received IncreaseDecreaseInAccruedInterestNetOfInterestReceived	-2169000	usd
CY2024Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-149157000	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-84067000	usd
CY2024Q1	us-gaap	Payments To Acquire Available For Sale Securities Debt PaymentsToAcquireAvailableForSaleSecuritiesDebt	84197000	usd
CY2023Q1	us-gaap	Payments To Acquire Available For Sale Securities Debt PaymentsToAcquireAvailableForSaleSecuritiesDebt	198822000	usd
CY2024Q1	us-gaap	Proceeds From Sale And Maturity Of Available For Sale Securities ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities	182607000	usd
CY2023Q1	us-gaap	Proceeds From Sale And Maturity Of Available For Sale Securities ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities	11993000	usd
CY2024Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	357000	usd
CY2023Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	35000	usd
CY2024Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	98053000	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-186864000	usd
CY2024Q1	us-gaap	Proceeds From Bank Debt ProceedsFromBankDebt	0	usd
CY2023Q1	us-gaap	Proceeds From Bank Debt ProceedsFromBankDebt	35000000	usd
CY2024Q1	us-gaap	Payments Of Debt Issuance Costs PaymentsOfDebtIssuanceCosts	0	usd
CY2023Q1	us-gaap	Payments Of Debt Issuance Costs PaymentsOfDebtIssuanceCosts	213000	usd
CY2024Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	573706000	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	52690000	usd
CY2024Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	522602000	usd
CY2023Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-218241000	usd
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	99915000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	331549000	usd
CY2024Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	622517000	usd
CY2023Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	113308000	usd
CY2024Q1	mdgl	Intangible Assets In Accounts Payable IntangibleAssetsInAccountsPayable	5000000	usd
CY2023Q1	mdgl	Intangible Assets In Accounts Payable IntangibleAssetsInAccountsPayable	0	usd
CY2024Q1	us-gaap	Use Of Estimates UseOfEstimates	<div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Use of Estimates </span></div>The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect certain reported amounts of assets and liabilities, and the reported amounts of revenues and expenses during the reporting periods. The Company bases its estimates on historical experience and various other assumptions that management believes to be reasonable under the circumstances. Changes in estimates are recorded in the period in which they become known. Actual results could differ from those estimates.
CY2023Q1	us-gaap	Debt Securities Available For Sale Realized Gain Loss DebtSecuritiesAvailableForSaleRealizedGainLoss	0	usd
CY2024Q1	us-gaap	Debt Securities Available For Sale Realized Gain Loss DebtSecuritiesAvailableForSaleRealizedGainLoss	0	usd
CY2024Q1	us-gaap	Restricted Cash Current RestrictedCashCurrent	1200000	usd
CY2023Q4	us-gaap	Restricted Cash Current RestrictedCashCurrent	0	usd
CY2024Q1	us-gaap	Cash And Cash Equivalents Fair Value Disclosure CashAndCashEquivalentsFairValueDisclosure	622517000	usd
CY2024Q1	mdgl	Deferred Tax Assets Percentage Of Valuation Allowance DeferredTaxAssetsPercentageOfValuationAllowance	1
CY2024Q1	us-gaap	Net Income Loss NetIncomeLoss	-147500000	usd
CY2024Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-1483800000	usd
CY2024Q1	us-gaap	Sale Of Stock Consideration Received On Transaction SaleOfStockConsiderationReceivedOnTransaction	574000000	usd
CY2024Q1	us-gaap	Cash And Cash Equivalents Fair Value Disclosure CashAndCashEquivalentsFairValueDisclosure	622517000	usd
CY2024Q1	mdgl	Cash Cash Equivalents And Short Term Investments At Cost CashCashEquivalentsAndShortTermInvestmentsAtCost	1059235000	usd
CY2024Q1	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	57000	usd
CY2024Q1	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	229000	usd
CY2024Q1	us-gaap	Cash Cash Equivalents And Short Term Investments CashCashEquivalentsAndShortTermInvestments	1059063000	usd
CY2023Q4	us-gaap	Cash And Cash Equivalents Fair Value Disclosure CashAndCashEquivalentsFairValueDisclosure	99915000	usd
CY2023Q4	us-gaap	Cash And Cash Equivalents Fair Value Disclosure CashAndCashEquivalentsFairValueDisclosure	99915000	usd
CY2023Q4	mdgl	Cash Cash Equivalents And Short Term Investments At Cost CashCashEquivalentsAndShortTermInvestmentsAtCost	633663000	usd
CY2023Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	476000	usd
CY2023Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	8000	usd
CY2023Q4	us-gaap	Cash Cash Equivalents And Short Term Investments CashCashEquivalentsAndShortTermInvestments	634131000	usd
CY2024Q1	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	0	usd
CY2023Q4	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	0	usd
CY2024Q1	us-gaap	Inventory Work In Process Net Of Reserves InventoryWorkInProcessNetOfReserves	235000	usd
CY2023Q4	us-gaap	Inventory Work In Process Net Of Reserves InventoryWorkInProcessNetOfReserves	0	usd
CY2024Q1	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	619000	usd
CY2023Q4	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	0	usd
CY2024Q1	us-gaap	Inventory Net InventoryNet	854000	usd
CY2023Q4	us-gaap	Inventory Net InventoryNet	0	usd
CY2024Q1	mdgl	Accrued Contract Research Costs Current AccruedContractResearchCostsCurrent	52974000	usd
CY2023Q4	mdgl	Accrued Contract Research Costs Current AccruedContractResearchCostsCurrent	50737000	usd
CY2024Q1	mdgl	Accrued Other Clinical Study Related Costs Current AccruedOtherClinicalStudyRelatedCostsCurrent	3775000	usd
CY2023Q4	mdgl	Accrued Other Clinical Study Related Costs Current AccruedOtherClinicalStudyRelatedCostsCurrent	3724000	usd
CY2024Q1	mdgl	Accrued Manufacturing And Drug Supply Current AccruedManufacturingAndDrugSupplyCurrent	1284000	usd
CY2023Q4	mdgl	Accrued Manufacturing And Drug Supply Current AccruedManufacturingAndDrugSupplyCurrent	9705000	usd
CY2024Q1	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	16952000	usd
CY2023Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	17030000	usd
CY2024Q1	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	13241000	usd
CY2023Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	6814000	usd
CY2024Q1	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	4045000	usd
CY2023Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	1970000	usd
CY2024Q1	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	92271000	usd
CY2023Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	89980000	usd
CY2022Q2	us-gaap	Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights	14899	shares
CY2022Q2	us-gaap	Warrants And Rights Outstanding WarrantsAndRightsOutstanding	600000	usd
CY2023Q3	us-gaap	Warrants And Rights Outstanding WarrantsAndRightsOutstanding	900000	usd
CY2024Q1	us-gaap	Long Term Debt Maturities Repayments Of Principal Remainder Of Fiscal Year LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear	9619000	usd
CY2024Q1	us-gaap	Long Term Debt Maturities Repayments Of Principal In Next Twelve Months LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths	12768000	usd
CY2024Q1	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Two LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo	79604000	usd
CY2024Q1	mdgl	Long Term Debt Maturity After Year Three LongTermDebtMaturityAfterYearThree	53387000	usd
CY2024Q1	us-gaap	Debt Instrument Carrying Amount DebtInstrumentCarryingAmount	155378000	usd
CY2024Q1	us-gaap	Interest Expense Debt Excluding Amortization InterestExpenseDebtExcludingAmortization	34225000	usd
CY2024Q1	us-gaap	Debt Instrument Unamortized Discount DebtInstrumentUnamortizedDiscount	5018000	usd
CY2024Q1	us-gaap	Long Term Debt LongTermDebt	116135000	usd
CY2024Q1	mdgl	Common Stock Voting Rights Number CommonStockVotingRightsNumber	1	vote
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	2355779	shares
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	79.94
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	135518	shares
CY2024Q1	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	229.77
CY2024Q1	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	18319	shares
CY2024Q1	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	74.90
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	14751	shares
CY2024Q1	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	88.80
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	2458227	shares
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	88.18
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	1850988	shares
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	75.49
CY2024Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	19902000	usd
CY2023Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	11250000	usd
CY2024Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	19902000	usd
CY2023Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	11250000	usd
CY2024Q1	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized	177300000	usd
CY2024Q1	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1 EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1	P3Y
CY2024Q1	us-gaap	Revenues Revenues	0	usd
CY2023Q1	us-gaap	Revenues Revenues	0	usd
CY2023	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	1600000	usd
CY2024Q1	ecd	Rule10b51 Arr Trmntd Flag Rule10b51ArrTrmntdFlag	false
CY2024Q1	ecd	Non Rule10b51 Arr Trmntd Flag NonRule10b51ArrTrmntdFlag	false
CY2024Q1	ecd	Non Rule10b51 Arr Adopted Flag NonRule10b51ArrAdoptedFlag	false

Files In Submission

Name	View Source	Status
0001628280-24-020865-index-headers.html	Edgar Link	pending
0001628280-24-020865-index.html	Edgar Link	pending
0001628280-24-020865.txt	Edgar Link	pending
0001628280-24-020865-xbrl.zip	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
mdgl-202403301xex311.htm	Edgar Link	pending
mdgl-20240331.htm	Edgar Link	pending
mdgl-20240331.xsd	Edgar Link	pending
mdgl-20240331xex101.htm	Edgar Link	pending
mdgl-20240331xex102.htm	Edgar Link	pending
mdgl-20240331xex103.htm	Edgar Link	pending
mdgl-20240331xex312.htm	Edgar Link	pending
mdgl-20240331xex321.htm	Edgar Link	pending
mdgl.jpg	Edgar Link	pending
mdgl1.jpg	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
mdgl-20240331_cal.xml	Edgar Link	unprocessable
mdgl-20240331_def.xml	Edgar Link	unprocessable
mdgl-20240331_lab.xml	Edgar Link	unprocessable
mdgl-20240331_pre.xml	Edgar Link	unprocessable
mdgl-20240331_htm.xml	Edgar Link	completed
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$MDGL
Madrigal Pharmaceuticals Inc Stock $mdgl

2024 Q2 Form 10-Q Financial Statement

#000162828024020865 Filed on May 07, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$MDGL Madrigal Pharmaceuticals Inc Stock $mdgl

2024 Q2 Form 10-Q Financial Statement

#000162828024020865 Filed on May 07, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$MDGL
Madrigal Pharmaceuticals Inc Stock $mdgl